PT - JOURNAL ARTICLE AU - Selvakumari, M. AU - AnandKarthikeyan, D. AU - Ramakrishnan, R. AU - George, Melvin TI - Role of Growth factors (HB-EGF, VEGF-A) and Immunotolerance Mediators (TNF-αIFN-γ,PD-L1 and IL-10) in Acute and Chronic Otitis Media AID - 10.1101/2020.09.16.20195610 DP - 2020 Jan 01 TA - medRxiv PG - 2020.09.16.20195610 4099 - http://medrxiv.org/content/early/2020/09/21/2020.09.16.20195610.short 4100 - http://medrxiv.org/content/early/2020/09/21/2020.09.16.20195610.full AB - Objectives There is an increasing evidence of immune mediated mechanism in the etiopathogenesis of Otitis Media – ‘middle ear inflammation’. The aim of the present study was to determine the expression of important circulatoryregulators of‘immunotolerance’as biomarkers.Materials and Methods In this cross sectional study, a total of 44 OM patients and 37 controls were included. Blood plasma level of HB-EGF, IL-10, TNF-α, IFN-γ, PD-L1 and VEGF-A were quantified using Human Magnetic Luminex assay.Results The study showed statistical significant differences in the levels of VEGF-A between OM patients with and without tympanic membrane perforations (p<0.05). Moreover, we found comparatively higher level of PD-L1 in OM patients than controls. However, the level of growth factor HB-EGF, is significantly higher in controls than the cases (p<0.05). There was also a correlation between the levels of HB-EGF and VEGF-A and the severity of the disease condition.Conclusions Role of inflammatory mediators and cytokines like PD-L1, IFNγ, TNFα and IL-10in OM patients as a biomarkers are very minimal. VEFG-A have a significant role in the pathogenesis of OM.Further studies are required for better understanding of the role of these immunosuppressive mediators in the eitopathogenesis of OM.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSelvakumari Mathiyalagan was supported by a Research Associate Fellowship (2017-2018) from the Department of Biotechnology. This study was partly supported by DBT-RA-Contingency grant of Selvakumari MathiyalaganAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional Ethics committee has approved this studyAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data referred to in the manuscript are original includes tables and figures